Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsRaw MaterialsReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Outlook Therapeutics (OTLK) Raw Materials (2025)

Outlook Therapeutics (OTLK) has disclosed Raw Materials for 1 consecutive years, with $2.4 million as the latest value for Q4 2025.

  • On a quarterly basis, Raw Materials changed N/A to $2.4 million in Q4 2025 year-over-year; TTM through Dec 2025 was $2.4 million, a N/A change, with the full-year FY2025 number at $2.4 million, changed N/A from a year prior.
  • Raw Materials was $2.4 million for Q4 2025 at Outlook Therapeutics, roughly flat from $2.4 million in the prior quarter.
  • In the past five years, Raw Materials ranged from a high of $2.4 million in Q3 2025 to a low of $2.4 million in Q3 2025.